Programming Therapeutics to Adapt Faster than Diseases Evolve
We set out to create a new paradigm of disease treatment: precision-engineered, CRISPR-based therapeutics that irreversibly disrupt disease at the genomic level.
Diseases move fast;
the moonshot
Therapeutic Development that Outpaces Disease
Bringing a new drug to market takes more than 10 years and costs over $2 billion—and most of that effort happens before a single patient is ever treated. In the meantime, diseases mutate, resistance spreads, and outbreaks outpace development cycles.
At Seek Labs, we set out to change that equation.
What if we could develop new therapeutics in days, not years?
What if we could target diseases at their genetic core—eliminating their ability to spread, adapt, or survive?
What if we could build a platform that’s programmable, fast, and precise enough to stay ahead of the next threat?
We didn’t just ask the questions—we also built the answer.
The Breakthrough
Programmable Target Ablation Platform (PTAP)™: Seeking and Destroying Disease
Unlike traditional antivirals or antibiotics—which often inhibit replication or slow disease progression and vaccines that rely on immune system priming and can struggle to keep pace with mutating pathogens—our Programmable Target Ablation Platform (PTAP)™ is designed to permanently disable diseases by disrupting the genetic sequences essential to their survival or function And because it’s programmable, the platform can be tailored to new threats as they emerge, across both human and animal health.
Our platform allows immediate development of precision therapeutics for emerging threats, drastically outperforming traditional antivirals, antibiotics, and vaccines.
Instead of chasing one disease strain at a time, we can proactively neutralize entire families, ensuring comprehensive protection against evolving threats.
With programmable precision, we can seek and permanently destroy diseases, leaving healthy cells untouched and delivering unparalleled safety and efficacy.
The Tech behind the magic
Programmable Therapeutic Platform Powered by BioSeeker™
Seek Labs’ therapeutic platform is a next-generation system for programmable, genomic-level disease targeting. Powered by our BioSeeker™ discovery engine, it enables the rapid development of precise, adaptable therapeutics.
How it works
Our end-to-end process—rooted in genomic precision, modular design, and rapid iteration—allows Seek Labs to accelerate the therapeutic timeline from years to months, and to generate therapeutics capable of addressing a wide range of evolving threats directly at their source.
DISCOVERY &
DESIGN
BioSeeker-Powered Target Identification
We begin with disease analysis using BioSeeker™. By scanning large-scale genomic data, BioSeeker identifies high-conservation, high-impact genetic targets that are most critical to disease viability and least likely to mutate.
Rational Design & Safety Profiling
Once targets are selected, we use in silico modeling and sequence analysis to prioritize safety, minimize off-target effects, and optimize guide designs. This helps reduce early-stage development risks and enables better alignment with regulatory expectations.
BUILD & VALIDATION
Rapid Design & Iterative Build
PTAP constructs are designed in-house using our programmable guide architecture. Multiple guides are often developed simultaneously to address variant diversity or multiple genomic targets. This parallelized, modular approach compresses early development timelines and allows for flexible adaptation to different diseases or strains.
Multiplexed Pathogen Targeting
Our system supports the development of multiplexed constructs—allowing one therapeutic to target multiple strains or species within a disease family. This enables preemptive coverage of variants and enhances durability against mutation-driven resistance.
Therapeutic Validation
Constructs are validated through in vitro and in vivo studies in collaboration with partners, focusing on safety, specificity, and efficacy. This stage ensures readiness for regulatory advancement and downstream development (e.g., delivery, dosing, clinical translation). This process allows Seek Labs to accelerate therapeutic development.
This end-to-end process—rooted in genomic precision, modular design, and rapid iteration—allows Seek Labs to accelerate the therapeutic timeline from years to months, and to generate therapeutics capable of addressing a wide range of evolving threats directly at their source.
Turning Intelligence into Action, One Target at a Time
Global Therapeutic Atlas
Powered by BioSeeker™
At the heart of Seek Labs’ therapeutic pipeline is the Global Therapeutic Atlas—a continuously updated map of high-impact genetic targets across zoonotic, pandemic, and drug-resistant diseases. Designed as both an internal R&D engine and a collaboration resource, the Atlas informs rapid response readiness, strategic partnerships, and stockpile prioritization around the world.
real-world impact
Cracking the code on African Swine Fever Virus (ASFV)
ASFV has caused over $196 billion in global economic losses and now spans 52 countries, making it one of the most urgent threats to food security and animal health worldwide.
In 2024, we demonstrated the power of our programmable therapeutic platform in vivo—extending survival from 0% to 60% in pigs infected with African Swine Fever Virus (ASFV), a highly lethal disease with no globally approved treatment or vaccine.
This trial proved that programmable therapeutics aren’t just fast—they’re effective. BioSeeker enabled a therapeutic that turned a 0% survival rate into almost 60% survival. It’s a striking example of what can happen when BioSeeker and PTAP work together.
PTAP isn’t a hypothetical platform;it's already shown what’s possible when we target disease at its genetic source and program a solution.
Neglected Tropical Diseases (NTDs)
Affecting over a billion people globally, NTDs are often overlooked in traditional drug pipelines. PTAP provides a flexible approach to develop new therapeutics that expand access and equity—supporting global eradication goals and community resilience.
Rapidly Evolving Respiratory Viruses
Airborne pathogens are constantly mutating. PTAP enables fast reprogramming to match circulating strains—avoiding resistance and outpacing evolution.
Agricultural and Livestock Pathogens
Animal health is global health. PTAP enables targeted treatment of veterinary pathogens to protect food security and rural economies.
Hemorrhagic Fevers & High-Fatality Outbreak Viruses
Hemorrhagic fever diseases demand fast, decisive countermeasures. Our platform enables rapid therapeutic design for viral families with pandemic potential—before they spiral out of control.
Zoonotic and Cross-Species Pathogens
The next pandemic could come from animals. With a shared platform that works across species, PTAP enables early intervention for viruses with zoonotic potential—at the human-animal interface.
Vector-Borne Diseases
Vector-borne Diseases are spreading to new geographies as climate conditions shift. Our platform can be tailored to create targeted therapies for these fast-moving threats.
Diseases Without Approved Treatments
Many pathogens have no approved antivirals or therapeutics. PTAP allows us to generate first-in-class therapeutic options where none exist today.
A New Therapeutic model
Responding at the Speed of Disease
From high-fatality viruses to neglected endemic diseases, Seek Labs’ programmable therapeutic platform is built to meet the urgent, unmet needs of patients and health systems around the world. By targeting the root genetic drivers of disease, PTAP offers a new model for precision medicine—one that works across geographies, species, and pathogen types.
why it matters
Because Diseases Are Winning—But We Can Change That
Seek Labs’ programmable therapeutic platform transforms therapeutic development. This matters for everyone.
Faster access to targeted, life-saving treatments—without the wait or guesswork.
New tools that enable confident, real-time treatment decisions—built for adaptability and accuracy.
Rapidly deployable countermeasures for known and emerging threats, no matter where they strike.
A next-generation platform for building, validating, and scaling precision therapeutics across high-priority diseases.
A new level of health resilience—designed to stop outbreaks before they start and to treat disease before it spreads.
We’re not just developing therapeutics—we’re fundamentally changing how the world responds to disease. Because every day we wait for traditional R&D to catch up, lives are lost. Let’s build a world where that wait is no longer necessary.
BioSeeker powers everything we do. It rapidly identifies, ranks, and optimizes genetic targets for both diagnostics and therapeutics—compressing timelines and increasing precision across Seek Labs’ full-stack development processes.
Learn more about how BioSeeker also drives development of SeekIt™, our molecular diagnostics platform.